Sahu Tarun, Jagzape Arunita Tushar, Sinha Meenakshi, Sinha Ramanjan, Verma Henu Kumar
Department of Physiology, All India Institute of Medical Sciences, Raipur 492099, Chhattīsgarh, India.
Department of Lung Health and Immunity, Helmholtz Zentrum Munich, Munich 85764, Bayren, Germany.
World J Virol. 2025 Jun 25;14(2):101693. doi: 10.5501/wjv.v14.i2.101693.
Sickle cell disease (SCD) is a genetic disorder that predisposes affected individuals to a range of complications, including an increased susceptibility to viral infections. These infections present significant clinical challenges due to the underlying immunocompromised state in SCD patients. This review examines the interaction between viral infections and SCD, highlighting the vulnerabilities and the impact of these infections on morbidity and mortality in this population. Advances in antiviral therapies have significantly improved outcomes, yet managing viral infections in SCD patients requires special consideration due to drug-to-drug interactions, altered pharmacokinetics, and the potential exacerbation of SCD-related complications. Additionally, vaccination strategies against viral infections and the emerging role of prophylactic antiviral treatments are discussed as critical components of infection prevention. By focusing on both established and novel antiviral treatments, this article aims to provide a comprehensive overview of the challenges and opportunities in managing viral infections in patients with SCD.
镰状细胞病（SCD）是一种遗传性疾病，使受影响的个体易患一系列并发症，包括对病毒感染的易感性增加。由于SCD患者潜在的免疫功能低下状态，这些感染带来了重大的临床挑战。本综述探讨了病毒感染与SCD之间的相互作用，强调了这些感染在此人群中的易感性以及对发病率和死亡率的影响。抗病毒疗法的进展显著改善了治疗效果，但由于药物相互作用、药代动力学改变以及SCD相关并发症可能加重，管理SCD患者的病毒感染需要特别考虑。此外，针对病毒感染的疫苗接种策略以及预防性抗病毒治疗的新作用作为感染预防的关键组成部分进行了讨论。通过关注既定和新型抗病毒治疗，本文旨在全面概述管理SCD患者病毒感染的挑战和机遇。
